Objective To observe the short-term effect and safety of hyperbaric oxygen combined with edaravone and ozagrel sodium in treating progressive cerebral infarction. Methods A total of 65 in-patients with acute progressive cerebral infarction were randomly divided into two groups: 33 in-patients in the trial group were treated by hyperbaric oxygen combined with edaravone and ozagrel sodium, while the other 32 in-patients in the control group were treated by edaravone and ozagrel sodium. The course of treatment was 14 days. The following indications were assessed before and after the treatment respectively: the national institutes of health stroke scale (NIHSS), activities of daily living (ADL), and clinical effects. Results This study showed that the scores of both ADL and NIHSS in the trial group were higher than those in the control group, with significant differences (Plt;0.05). The clinical effective rate of the trial group was 90.91% which was obviously higher than the control group with a significant difference (P=0.028). There were no obvious adverse reactions in both groups. Conclusion Hyperbaric oxygen combined with both edaravone and ozagrel sodium is notable in short-term effect and safe, thus it is worth being popularized in clinical treatment.
目的 探讨尤瑞克林对不同结构性影像类型进展性脑梗死的CT与临床效果。 方法 2007年3月－2011年6月按入院时不同结构性影像类型将进展性脑梗死分为大灶梗死、中灶梗死、小灶梗死及腔隙梗死4型，共235例，采用分层随机分组的方法将患者分为尤瑞克林组（治疗组）119例，对照组116例。两组基础用药均为疏血通6 mL+生理盐水250 mL静脉滴注，胞磷胆碱0.5 g+生理盐水250 mL静脉滴注，阿司匹林0.1 g口服，以上用药均为1次/d，连用4周。治疗组同时给予生理盐水100 mL+尤瑞克林0.15 PNAu静脉滴注，对照组同时给予生理盐水100 mL静脉滴注，1次/d，连用7～14 d，两组治疗前后均测量梗死的最大层面最大梗死灶的长度与宽度，计算并记录梗死面积；统计分析各型的临床疗效。 结果 ① 梗死面积改变：治疗前各亚型治疗组与对照组梗死面积差异均无统计学意义（P＞0.05）；治疗后，大灶梗死组、中灶梗死组、小灶梗死组中的治疗组梗死面积均比治疗前显著缩小（P＜0.01），而对照组的梗死面积较治疗前差异无统计学意义（P＞0.05）；腔隙梗死组中，治疗组及对照组治疗后梗死面积均无明显改变（P＞0.05）。② 临床疗效：各亚型进展性脑梗死，治疗组均取得优于对照组的效果；大灶梗死及中灶梗死的显著进步率分别为47.6%和66.7%，而对照组的显著进步率分别为0.0%和33.3%。 结论 大灶梗死组、中灶梗死组、小灶梗死组进展性脑梗死使用尤瑞克林治疗后梗死面积均比治疗前明显缩小；各亚型进展性脑梗死使用尤瑞克林后临床疗效均优于对照组，尤其是大灶梗死及中灶梗死的临床效果更加显著。
目的:研究疏血通联合奥扎格雷钠治疗进展性脑梗死的临床疗效。方法: 将62例进展性脑梗死患者随机分为两组,对照组30例,治疗组32例。对照组静滴丹参40mL,1/d,羟乙基淀粉40氯化钠500mL,1/d,治疗组静滴疏血通6mL,1/d,奥扎格雷钠160mg,1/d,疗程均为14天。观察两组总有效率及治疗前后神经功能缺损评分、血液流变学、脑血管平均血流速度的改变。结果: 治疗组对进展性脑梗死的总有效率为93.8%,对照组为73.3%,两组相比有显著性差异(Plt;0. 05)。治疗组治疗前后神经功能缺损评分、血液流变学指标、脑血流量均有明显改善,差异有显著性,而对照组则不明显。结论: 疏血通与奥扎格雷钠联合治疗进展性脑梗死能起到协同作用,可有效改善进展性脑梗死患者脑部血液循环,减轻梗死后脑组织的缺血坏死风险,最大程度降低病残率,改善患者的预后,其疗效优于丹参与羟乙基淀粉40氯化钠,且安全性高,是治疗进展性脑梗塞较为理想的药物。